Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 5, 2009

View Archived Issues

Biocompatibles and AstraZeneca sign agreements for GLP-1 analogue

Cytokinetics retains rights to ispinesib and SB-743921

MediciNova issues proposal to acquire Avigen

Ligand completes acquisition of Pharmacopeia

Novartis and AlphaVax sign exclusive license agreement for CMV vaccines

Daiichi Sankyo enters vaccine alliance with The Kitasato Institute

LifeCycle commences LCP-Tacro phase III trials

BI-2536 active and well tolerated in elderly patients with relapsed/refractory AML

Nabi reaches agreement with FDA on SPA for a phase III clinical trial of NicVax

Sosei reacquires commercialization rights to opioid analgesic AD-923 from Mundipharma

Salix receives FDA complete response letter for balsalazide

Savient's pegloticase BLA for treatment-failure gout granted priority review

FDA issues complete response letter to Ipsen for Dysport BLA in cervical dystonia

Clinical benefit seen with INCB-018424 in myelofibrosis

Results reported for phase II study of SGN-40 in diffuse large B-cell lymphoma

Breast cancer progression may be inhibited by fluvastatin

King acquires Alpharma

FDA accepts for filing Northfield Laboratories' BLA for PolyHeme

GTx submits NDA for toremifene for bone fracture prevention in prostate cancer

Johnson & Johnson plans short-form merger of Omrix

Urigen amends licence agreement with UCSD for URG-101

Novel matrix metalloproteinase inhibitors from Array BioPharma

New chymase inhibitors for cardiovascular diseases patented at Boehringer Ingelheim

New mgluR2 ligands/5-HT2A antagonists described in Abbott patent

SARS DNA vaccine safe, immunogenic in phase I study

Popular Stories

Today's news in brief
BioWorld
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...
New mechanism of action identified for QC-6352
BioWorld Science
QC-6352 is a small molecule developed to inhibit the histone demethylase 4 (KDM4) that has shown potent antitumoral activity and which has a derivative named...
VST Bio’s VB-001 is neuroprotector after stroke
BioWorld Science
At the recent International Stroke Conference, researchers from VST Bio Corp. and Yale University presented preclinical data regarding VB-001, a monoclonal...